From 1 August 2009 clopidogrel can be prescribed in combination with aspirin as an authority (streamlined) benefit on the Pharmaceutical Benefits Scheme (PBS) after coronary artery stent insertion.1Previously a PBS subsidy was available for the treatment of acute coronary syndrome (ACS), and for prevention of recurrence of ischaemic stroke, transient cerebral ischaemic events, myocardial infarction or unstable angina. The extended PBS listing allows patients who
require a stent to have equitable access to clopidogrel therapy.
The Pharmaceutical Benefits Advisory Committee noted that there is evidence that prescribing clopidogrel, in combination with aspirin, is best clinical practice to prevent blood clots reforming after cardiac stent insertion.1
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.